Effects of escitalopram in the treatment of treatment-resistant depression
10.3760/cma.j.issn.1008-6706.2020.14.014
- VernacularTitle:艾司西酞普兰治疗难治性抑郁症的效果观察
- Author:
Xiejun HU
1
;
Hong FENG
;
Songtao LI
;
Fei SHEN
Author Information
1. 浙江省，绍兴市第七人民医院精神二科 312000
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(14):1725-1728
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical effect of escitalopram in the treatment of treatment-resistant depression (TRD).Methods:A total of 90 patients with TRD who admitted to the Seventh People's Hospital of Shaoxing from January 2017 to January 2019 were divided into group A and group B by the random number table method, with 45 cases in each group.All subjects were given conventional treatment.On this basis, group A was treated with citalopram, and group B was treated with escitalopram.The clinical effect and adverse reactions were compared between the two groups.Results:The scores of Hamilton depression scale (HAMD) and clinical global impression (CGI) of group B after medication[(8.27±1.44)points and (2.82±0.74)points] were significantly lower than those of group A[(15.14±2.35)points and (4.87±1.33)points]( t=16.721, 9.035, all P<0.05). The total effective rate in group B after treatment (91.11%) was higher than that in group A (71.11%) (χ 2=5.874, P<0.05). The incidence of adverse reactions in group B (8.88%) was lower than that in group A (24.44%) (χ 2=3.920, P<0.05). Conclusion:Escitalopram is significantly effective in the treatment of TRD.It can effectively relieve the symptoms and reduce the incidence of adverse reactions.
